Introduction
Rheumatoid arthritis (RA) is a chronic disease characterized by inflammation of the joints with concomitant destruction of both cartilage and bone. 1 Although the causes of RA are not fully understood, various experimental and clinical studies suggest that proinflammatory cytokines, particularly tumor necrosis factor-a (TNF-a), play an important role in RA pathogenesis. [2] [3] [4] [5] [6] TNF concentrations are increased in the synovial fluid of persons with active RA 7, 8 and increased plasma levels of TNF are associated with joint pain. 9 There are two distinct type cell-surface TNF receptors (TNFRs), designated p55 and p75. 10, 11 Soluble, truncated versions of membrane TNFRs (sTNFR), consisting of only the extracellular, ligand-binding domain, are present in body fluids and are thought to be involved in regulating TNF activity. 12, 13 Recombinant sTNFR:Fc fusion proteins, which are engineered sTNFRs linked to the Fc portion of immunoglobulin G1(IgG1), have been developed for therapeutic neutralization of TNF. 14, 15 Several experimental and clinical studies demonstrated that the p75 TNFR:Fc fusion protein was effective in RA while the p55 TNFR:Fc fusion protein worked, but to a lesser extent. [16] [17] [18] Effective control of autoimmune arthritis requires prolonged neutralization of proinflammatory mediators, and gene therapy offers several potentially unique advantages over previous protein therapies. With the recent advances in gene therapy, the TNFR gene has been delivered by retrovirus and adenovirus-based vectors intraarticularly or systemically to achieve anti-inflammatory effects with varying degrees of success. [19] [20] [21] [22] Among various viral and nonviral techniques for gene transfer in vivo, the direct injection of plasmid DNA into muscle is probably the simplest, most inexpensive, and safest method. 23 Recently, plasmid DNA injection followed by in vivo electroporation has been shown to be effective for introducing DNA into murine muscles. 24, 25 In the present study, we applied this method for the delivery of p75 sTNFR:Fc in a murine collagen-induced arthritis (CIA) model. A plasmid vector encoding the human sTNFR:Fc gene was introduced into the muscles of arthritic mice, and its effect on arthritis was measured by macroscopic evaluation of paws, determination of the level of several cytokines, and histologic findings in synovium and cartilage.
Results
In vivo expression of sTNFR:Fc by electroporation As a plasmid expression vector for intramuscular gene therapy, we used pCK, which has been shown to drive high-level gene expression in the skeletal and cardiac muscles of mice. 26, 27 The human sTNFR:Fc coding sequence was cloned to pCK, resulting in pCKsTNFR:Fc. (Figure 1a) . Immunoblotting of the culture supernatant from 293T cells transfected with pCKsTNFR:Fc revealed the expression of a 76-kDa protein, the expected size for human sTNFR:Fc (Figure 1b ). We also examined the level of sTNFR:Fc in culture supernatant by ELISA. As shown in Figure 1c , 18.1 ng/ml of sTNFR:Fc was produced from 1 Â 10 5 of 293T cells transfected with pCK-sTNFR:Fc, while less than 10 pg/ ml was detected in the same number of cells transfected with the control plasmid.
To determine whether the electroporation-mediated transfer of pCK-sTNFR:Fc produced physiologically significant levels of protein, one site of the left gastrocnemius muscle of each DBA/1 mouse was injected with different amounts of DNA with or without in vivo electroporation. As a control, the same amount of vector DNA (pCK) was used. At 6 days after DNA injection, the serum concentrations of sTNFR:Fc were determined by ELISA. As shown in Figure 2a , significant levels of sTNFR:Fc were produced by in vivo electroporation in a dose dependent manner, while the sTNFR:Fc levels of the control mice similarly treated with the vector DNA or sTNFR:Fc DNA without electroporation were less than 1 pg/ml, the detection threshold of the assay. Based on this result, 15 mg/per mouse of DNA was chosen for later experiments.
Next, we investigated how long the sTNFR:Fc could be expressed by a single in vivo electroporation. We injected 15 mg/per mouse of DNA to the gastrocnemius muscle of mice with or without in vivo electroporation. As a control, the same amount of vector DNA was injected into another group of mice with in vivo electroporation. The serum concentrations of sTNFR:Fc were examined by ELISA at appropriate times after electroporation. As shown in Figure 2b , significant levels (higher than 100 pg/ml) of serum sTNFR:Fc were detected for 7 days after injection of pCK-sTNFR:Fc (Po0.01, compared with pCK). The serum sTNFR:Fc concentration rapidly increased immediately after electroporation, reaching its peak at 2.3 ng/ml on day 5, while that of the control mice similarly treated with the empty pCK vector was less than 1 pg/ml, the detection threshold of the assay. The level of serum sTNFR:Fc in control mice treated with sTNFR:Fc without electroporation was less than 1 pg/ ml. We have also completed similar experiments using NOD/SCID mice. In contrast to the above results, significant levels of sTNFR:Fc were detected in the sera of NOD/SCID mice even 30 days after DNA treatment (Figure 2c ), suggesting the possible role of immune response in a relatively short period of sTNFR:Fc expression in immunocompetent mice.
We also examined the levels of sTNFR:Fc in the knee joints and the injected areas of muscles. As seen in Figure  2d , significant levels of sTNFR:Fc were detected in the muscles even at 20 days after in vivo electroporation. In the knee joints, the level of sTNFR:Fc was low but still significantly higher in sTNFR:Fc DNA-treated mice as compared with control DNA-treated mice 5 days after DNA treatment (Figure 2e ). In addition, we analyzed the effects of in vivo electroporation on the local inflammation in the injected areas of muscles by histological examination. Increased inflammation was observed in both the vector DNA-treated group and the sTNFR:Fc DNA-treated group 1 day after in vivo electroporation, but these phenomena almost disappeared 20 days after DNA treatment (Figure 3 ). There was no significant difference in the degree of inflammation between the vector DNA-and the sTNFR:Fc DNA-treated group. These results clearly indicate that in vivo electroporation is a highly efficient method for the systematic delivery of sTNFR:Fc.
Delivery of pCK-sTNFR:Fc by in vivo electroporation prevents CIA in mice
We tested whether the in vivo electroporation-mediated gene transfer of sTNFR:Fc could be used to prevent experimental arthritis. DBA/1 mice were immunized with bovine type II collagen, then 21 days after the initial immunization the mice were boosted with the same antigen. At 2 days after the boosting, the mice were divided into two groups. pCK-sTNFR:Fc (15 mg/per mouse) was injected into one site in the gastrocnemius Electrotransfer of sTNFR:Fc DNA inhibits CIA J-M Kim et al muscle of each mouse followed by in vivo electroporation in one group. As a control, the same amount of a control plasmid lacking the sTNFR:Fc coding sequence, pCK, was used for a separate group of mice.
The incidence of arthritis in the paws was assessed by macroscopic examination such as joint swelling and erythema every 3 or 5 days until 20 days following boosting. As shown in Figure 4a , the increase of paw At 20 days following boosting, the incidence of moderate to severe arthritis (Xindex 2) was seen in 72% of the paws of those mice which had received control plasmid DNA, while it was only evident in 42% of the paws of those mice treated with pCK-sTNFR:Fc (Po0.05) ( Figure  4b) . Similarly, the incidence of severe arthritis (Xindex 3) was seen in 60% of the paws of mice injected with pCK, versus only 31% of the paws of mice treated with pCKsTNFR:Fc 20 days after boosting (Po0.05) (Figure 4c ). However, there was no significant difference in the incidence of arthritis (Xindex 1) between sTNFR:Fc DNA and the control DNA groups (data not shown). These results suggested that electroporation-mediated transfer of pCK-sTNFR:Fc could efficiently reduce the incidence of moderate-to-severe CIA and that under our experimental system, beneficial effects of a single electroporation-mediated gene transfer lasted for a minimum of 18 days following treatment.
Delivery of pCK-sTNFR:Fc by in vivo electroporation decreased the severity of synovitis and cartilage erosion
We also assessed the incidence of arthritis in the knee joints by histological examination. Sections stained with hematoxylin and eosin showed that synovial proliferation and inflammatory cell infiltration were significantly decreased in the knee joints of mice treated with sTNFR:Fc, as compared with those of mice injected with a control plasmid (Figure 5a and b) . Comparison of the histological grades of synovitis between the sTNFR:Fctreated group and the control group showed that the difference was statistically significant (Po0.05) ( Figure  5c ). When pCK-sTNFR:Fc was injected, thinning and hyalinization of the cartilage were also inhibited ( Figure  6 ). Safranin O-staining of proteoglycan in the cartilage showed that the proteoglycan was well-preserved in the joints of mice treated with sTNFR:Fc, but not in the joints treated with control plasmid DNA (Figure 6a and b) . A statistically significant difference was found in the severity of cartilage erosion between the sTNFR:Fctreated group and the control groups (Po0.05) ( Figure  6c ). These results demonstrated that electroporationmediated delivery of pCK-sTNFR:Fc efficiently reduced the degree of histopathologic changes in the knee joints of CIA mice. To further clarify the mechanisms underlying the favorable effects of sTNFR:Fc, the expression levels of inflammatory cytokines were measured by ELISA. In the sTNFR:Fc-treated mice, the production of IL-1b and IL-12 were reduced to 69 and 16%, respectively, compared with the levels seen in the control vector-treated mice (Po0.01) (Figure 7 ), while the level of IL-17 and wWF remained unchanged in the sTNFR:Fc-treated mice as compared with the control mice. These results suggested that delivery of sTNFR:Fc DNA by electroporation could efficiently reduce the incidence of CIA by modulating the levels of inflammatory cytokines such as IL-1b and IL-12.
Discussion
The findings of the present study demonstrate that delivery of plasmid DNA containing cDNA for human sTNFR:Fc by in vivo electroporation could reduce the incidence and severity of murine CIA and that the beneficial effects last for 18 days after a single treatment. It further indicates that electrotransfer of sTNFR:Fc DNA reduces the level of IL-1b and IL-12 in the joints of treated CIA mice. TNF-a appears to be an important mediator of inflammation in RA.
2-4 TNF-a induces the release of matrix metalloproteinases from neutrophils, fibroblasts, and chondrocytes. 28, 29 It is well known that TNF-a can induce the expression of endothelial adhesion molecules involved in the migration of leukocytes to extravascular sites of inflammation as well as stimulate the release of other proinflammatory cytokines. 30, 31 Genetically engineered fusion proteins consisting of two identical chains of the recombinant soluble TNF-receptor (sTNFR) monomer fused with the Fc domain of IgG1 have been developed for the treatment of TNF-associated diseases. 14, 32 In this study, we demonstrated that electrotransfer of sTNFR:Fc DNA could reduce the incidence of CIA and the levels of IL-1b and IL-12. It has been reported that IL-1b and IL-12 each play an important role in the pathogenesis of arthritis. 3, [33] [34] [35] [36] Therefore, it is likely that one of the possible mechanisms involved in the suppression of arthritis by sTNFR:Fc is the inhibition of TNF-a-induced production of IL-1b and IL-12. The inhibitory effect of sTNFR:Fc on the level of IL-12 also suggests that sTNFR:Fc may downregulate Th1 activity, since IL-12 is known to play a pivotal role in promoting the differentiation of Th1 responses and inducing IFNg production. 37 Randomized, double-blind, placebo-controlled trials showed that human p75 sTNFR:Fc fusion protein treatment yielded significant clinical benefits, with minimal toxicity, in patients with RA who had inadequate responses to other disease-modifying drugs. 17 Soluble cytokine receptors may have a distinct advantage over other TNF-neutralizing agents, such as monoclonal antibodies, in terms of immunogenicity. Indeed, no antibodies against sTNFR:Fc were detected in clinical studies involving patients with RA and normal volunteers. 17, 38 However, due to the chronic characteristics of autoimmune arthritis, subcutaneous injection of 25 mg sTNFR:Fc twice weekly is required to obtain a significant clinical benefit.
In contrast to protein therapy, gene therapy has the advantage of relatively long-lasting expression at low levels, and therefore allows for reduced frequency of administration. This consideration is especially important in chronic diseases, such as RA, which may require long-term therapy. The present study indicated that beneficial effects lasted at least 18 days per single injection of plasmid DNA encoding the cDNA of sTNFR:Fc followed in vivo electroporation. These observations suggested that gene therapy for RA using the delivery of a plasmid vector by electroporation might be a therapeutically plausible form of RA treatment. This plasmid DNA transfer method has several advantages over viral vectors. 23 A large quantity of highly purified plasmid DNA can be readily obtained at a relatively low cost, and gene transfer can be repeated without apparent immunological responses to the plasmid DNA vector. Furthermore, quality control of DNA production, an important step on an industrial scale, is expected to be much less complicated than other viral vectors.
The present study shows that significant levels of sTNFR:Fc in sera can be obtained for 7 days by a single in vivo electroporation procedure. It is significantly shorter than other cases using the mouse erythropoietin gene. 24 One possible explanation for the limited duration of human sTNFR:Fc expression surrounds the immune response to the human sTNFR:Fc protein in mice. This possibility is supported by the observation that the expression of human sTNFR:Fc lasts for 30 days in NOD/SCID mice under identical conditions. Therefore, a longer expression of sTNFR:Fc might be achieved in the human system.
To our knowledge, these results provide the first demonstration that electroporation-mediated delivery of plasmid containing cDNA for sTNFR:Fc can be used to modulate the disease process in an animal arthritis model. However, in order for electrogene therapy with naked DNA to become a viable form of clinical treatment, several important issues must first be addressed. For example, profound and extensive research concerning the issue of scale-up will be needed to apply this technology to a human being. Since the mouse is likely 1000-fold smaller than a human, the optimization of the amount of DNA, electricity, and the protocol of treatment has to be done to get a therapeutic effect in a human. The studies on the application of electroporation-mediated gene transfer to larger animals are ongoing. 39, 40 Recently, it has been reported that local gene transfer could result in a systemic therapeutic effect without systemic elevation of the therapeutic protein. 19, 41 Further investigation on the mechanism responsible for these phenomena may help to develop the clinically relevant protocol for electroporation-based gene delivery strategy for the treatment of human RA.
Materials and methods
Cloning of human sTNFR:Fc and construction of expression vector cDNAs encoding the human sTNFR and Fc regions of human IgG1 were cloned from total RNA prepared from human peripheral blood lymphocytes by reverse transcription (RT) -polymerase chain reaction (PCR) respectively. PCR primers were: 5 0 -ATGGCGCCCGTCGCCG TCTGGGCCGCGCT-3 0 and 5 0 -AGTACTCCCTTCAGC TGGGGGGCTGGGGCCCATT-3 0 for sTNFR; 5 0 -AG TACTGGCGACGAGCCCAAATCTTGTGACAAA-3 0 and 5 0 -TCATTTACCCGGGGACAGGGA-3 0 for the Fc region of human IgG1. The amplified cDNAs were initially cloned into the pGEM-Teasy plasmid (Promega, WI, USA), resulting in the pGEM-sTNFR and the pGEM-Fc, respectively. Following sequence confirmation, ScaI fragment of the pGEM-sTNFR, which contains the sTNFR cDNA, was cloned into the ScaI site of the pGEM-Fc, resulting in the pGEM-sTNFR:Fc. Subsequently, DNA fragment encoding sTNFR:Fc was cloned into the EcoRI site of the mammalian expression vector pCK, which has been previously described, 26 resulting in the pCK-sTNFR:Fc. The pCKsTNFR:Fc plasmid was purified using an EndoFree plasmid Maxi prep kit (Qiagen,Valencia, CA, USA), dissolved in 0.9% NaCl, diluted to 4 mg/ml and stored at À201C prior to use.
SDS-PAGE and Western blotting
pCK-sTNFR:Fc and pCK were transfected into 293T cells with FuGENE6 (Roche Diagnostics, Germany). At 2 days after transfection, the culture supernatants were mixed with a one-third volume of sodium dodecyl sulfate (SDS)
Electrotransfer of sTNFR:Fc DNA inhibits CIA J-M Kim et al sample buffer (75 mM Tris-HCl (pH6.8), 6% SDS, 15% glycerol, 15% 2-mercaptoethanol, and 0.015% bromophenol blue), heated at 981C for 5 min, and subjected to SDSpolyacrylamide gel electrophoresis (PAGE) on a 10% polyacrylamide gel. After electrophoresis, the samples were transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was incubated at room temperature for 3 h with horseradish peroxidase (HRP)-conjugated anti-human IgG (Pierce, Rockford, IL, USA), washed, and processed for autoradiography using chemiluminescence techniques (ECL kt: Amersham, IL, USA), according to the manufacturer's instructions.
Intramuscular DNA injection and electroporation
Mice were anesthetized with ketamine (1.35 mg/mouse)/ xylazine (66 mg/mouse). Aliquots of 30 ml of plasmid DNA (pCK-sTNFR:Fc or control pCK) at 0.25, 0.5, or 1 mg/ml in 0.45% NaCl were injected into gastrocnemius muscle of the left hind leg (total amount of DNA was 7.5, 15, or 30 mg per mouse). A total of 90 units of type VI-S hyaluronidase from bovine testes (Sigma, St. Louis, MO, USA) were resuspended in 50 ml of sterile saline solution and injected 10 min prior to electroporation as previously described. 42 Commercially available caliper electrodes (model 383, BTX, San Diego, CA, USA) were used for electroporation. The caliper electrodes were applied to the shaved skin on either side of the marked DNA injection point, and the calipers were closed to a gap of 5 mm, so that electrical contact with the skin was maximized. Consecutively square-wave electrical pulses were administered eight times using an ECM830 pulse generator (BTX, San Diego, CA, USA) at 200 V/cm and a rate of 1 pulse/s, with each pulse being 20 ms in duration.
Induction of CIA and treatment protocol DBA/1 mice (Charles River, MA, USA), aged 6-7 weeks at the start of experiments, were immunized intradermally at the base of the tail with bovine type II collagen (100 mg; Chondrex, WA, USA) and emulsified in Freund's complete adjuvant (GIBCO BRL, NY, USA). 43 On day 21, the animals were boosted with an intradermal injection of 100 mg type II collagen emulsified in Freund's incomplete adjuvant (GIBCO BRL, NY, USA). At 2 days after the boosting, the mice were divided into two groups and individually treated with either 15 mg of plasmid DNA containing cDNA for sTNFR:Fc or control plasmid. For each mouse, one site in the gastrocnemius muscle of the left hind leg received direct injections with plasmid DNA with the use of a 1-ml syringe and a 27-gauge needle (15 mg/30 ml for each mouse) followed by in vivo electroporation.
Macroscopic scoring of CIA
Paws were individually scored using a macroscopic system ranging from 0 to 4, as previously described, with a maximum score of 4 for each paw: 0¼normal; 1¼detectable arthritis with erythema; 2¼significant swelling and redness; 3¼severe swelling and redness from joint to digit; and, 4¼maximal swelling and deformity with ankylosis. 44 The thickness of each paw was also measured using a spring-load caliper. Scoring of arthritic index and measuring of paw thickness were done by two independent observers who were blinded with regard to the experimental groups.
Histologic processing and analysis of knee joints
Knee joints were dissected, fixed in 10% phosphatebuffered formalin for 2 days, decalcified in 10% EDTA for 7 days, and then embedded in paraffin. Standard frontal sections of 7 mm were prepared, stained with either hematoxylin/eosin or Safranin O/fast green. Histopathological changes were scored using the following parameters. The severity of synovitis (synovial proliferation and inflammatory cell infiltration) was scored using a four-point scale (0-3, where 0 is normal and 3 severe), 45 Cartilage destruction was separately graded on a scale from 0 to 4 for each joint where 0¼normal, 1¼dead chondrocyte, 2¼local destruction of superficial chodrocyte, 3¼multifocal destruction of chondrocyte/subchondral bone, and 4¼complete destruction of chondrocyte and massive destruction of subcondral bone. Scoring was performed on decoded slides by two observers, as previously described. 46 Measurement of cytokine levels in mouse serum, joint or muscle
The levels of human sTNFR:Fc in sera, joints, and the injected muscles and the levels of murine IL-1b, murine IL-12, murine IL-17, and von Willebrand factor (vWF) in ankles were measured using commercially available ELISAs for human TNFR (R&D Systems, Minneapolis, MN, USA), mIL-1b (R&D Systems), mIL-12 (R&D Systems), mIL-17 (R&D Systems), and human vWF (Asserachrom vWF kit; Roche, Tokyo, Japan), according to the manufacturer's recommendations. Briefly, the injected muscles were excised and homogenized in lysis buffer (25 mM Tris-HCl pH 7.4, 50 mM NaCl, 0.5% Nadeoxycholate, 2% NP-40, 0.2% SDS, protease inhibitors). In the case of joint tissues, whole mice knees and ankles were snap frozen in liquid nitrogen and were ground into powder by pestle, then lysed with the lysis buffer. The supernatants containing total protein were used to measure cytokine levels. In the case of serum, it was directly subjected to TNFR assays without any pretreatment. Levels of vWF were expressed as a percentage, in which the detected vWF was compared with that present in a human plasma calibration standard arbitrarily assigned a value of 100%. 43 The levels of cytokines were normalized to the total amount of protein prepared from tissue lysates, as measured by way of a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Statistical analysis
Differences between experimental groups were tested using the Mann-Whitney rank sum test, unless stated otherwise. P-values less than 0.05 were considered significant.
